Skip to main content
. 2023 Jan 31;299(3):102956. doi: 10.1016/j.jbc.2023.102956

Figure 4.

Figure 4

FRET dose–response of Hit compounds that decrease FRET by greater than 20%.A–P, Dose–response of Hit compounds AKBA (A), avermectin B1 (B), candesartan (C), closantel (D), docusate (E), ivermectin (F), micafungin (G), montelukast (H), moxidectin (I), nilotinib (J), oleic acid (K), ombitasvir (L), quinacrine (M), temsirolimus (N), vorapaxar (O), and zafirlukast (P) were tested on the in vitro actin-binding domain biosensor FRET. The chemical structures of these Hit compounds are shown in Figs. S3–S16. ∗p< 0.05 relative to dimethyl sulfoxide (DMSO) control, using Student’s unpaired t test. Data shown as individual data points, n = 3.